Logo
Aavika Shinde @go_65c4954fd6ef7
Vasomotor Menopausal Symptoms (VMS) Treatment Market to Surge USD 27.03 billion with Excellent CAGR of 6.20% by 2030

All of the top players' and brands' company profiles are thoroughly covered in the universal Vasomotor Menopausal Symptoms (VMS) Treatment Market study. The study's projected compound annual growth rate (CAGR) in percentage terms for a given time frame will assist the keyword market industry in making decisions based on future data. The market's consumption and sales are thoroughly examined in this study, which also highlights the leading companies in terms of sales, pricing, revenue, and market share (volume and value) in each region.

Explore Further Details about This Research Vasomotor Menopausal Symptoms (VMS) Treatment Market Report https://www.databridgemark...

As per the North American Menopause Society, up to 75% of females in the U.S. witness hot flashes around menopause. Vasomotor symptoms (VMS), including night sweats and hot flashes, are observed in around 68.5% of women as a result of menopause. The median duration of these symptoms is approximately 4 years, though around 10% of women continue to experience VMS as many as 12 years. The increasing incidence of vasomotor and menopausal symptoms such as hot flashes and night sweats among women during menopausal transition is anticipated to boost the market growth.

Data Bridge Market Research analyses a growth rate in the vasomotor menopausal symptoms (VMS) treatment market in the forecast period 2023-2030. The expected CAGR of vasomotor menopausal symptoms (VMS) treatment market is around 6.20% in the mentioned forecast period. The market was valued at USD 16.71 billion in 2022, and it would grow up to USD 27.03 billion by 2030. 
7 months ago

No replys yet!

It seems that this publication does not yet have any comments. In order to respond to this publication from Aavika Shinde, click on at the bottom under it